COMPASS Pathways announces publication of phase 2b study of

After a single 25mg dose of COMP360 psilocybin therapy, approximately 30% of patients with treatment-resistant depression (TRD) were in remission at...

Related Keywords

United States , Canada , United Kingdom , London , City Of , Friston , East Sussex , America , American , Canadian , Stephen Schultz , Amy Lawrence , Scott Aaronson , American Psychiatric Association , Institute For Advanced Diagnostics , Psychiatric Sciences , Linkedin , Drug Administration , Nasdaq , Other Common Mental Disorders Global Health , Exchange Commission , Sheppard Pratt Health System , Thenew England Journal , Sequenced Treatment Alternatives , Relieve Depression , Chief Science Officer , Advanced Diagnostics , Principal Investigator , New Orleans , Canadian Journal , Depression Rating Scale , North America , Breakthrough Therapy , Innovative Licensing , Access Pathway , Securities Act , Private Securities Litigation Reform Act , Global Crisis , Nasdaq Cmps , Compass Pathways ,